Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PDUFA IV Negotiations Underway With FDA, Industry Working In Harmony

Executive Summary

PhRMA will pursue earlier postmarketing commitment negotiations with FDA as part of a limited industry agenda for the third reauthorization of the Prescription Drug User Fee Act

You may also be interested in...



FDA Opposes Enzi/Kennedy Drug Safety Bill; Action More Likely Through PDUFA

Pending drug safety legislation from Sens. Michael Enzi (R-Wyo.) and Edward Kennedy (D-Mass.) may do more harm than good, FDA implied in comments submitted to the Senate Health Committee

FDA Opposes Enzi/Kennedy Drug Safety Bill; Action More Likely Through PDUFA

Pending drug safety legislation from Sens. Michael Enzi (R-Wyo.) and Edward Kennedy (D-Mass.) may do more harm than good, FDA implied in comments submitted to the Senate Health Committee

BIO, PhRMA Oppose Granting FDA Authority To Mandate Postmarket Studies

The Pharmaceutical Research & Manufacturers of America and the Biotechnology Industry Organization oppose granting FDA the power to require postmarketing studies

Related Content

UsernamePublicRestriction

Register

PS047072

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel